Literature DB >> 22075663

Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case.

Yoshiro Itatani1, Takashi Akiyoshi, Hiroya Kuroyanagi, Keiko Yamakawa, Rota Noaki, Tsuyoshi Konishi, Yoshiya Fujimoto, Masashi Ueno, Masatoshi Oya, Mitsukuni Suenaga, Toshiharu Yamaguchi.   

Abstract

A 60-year-old man underwent sigmoid loop colostomy for obstructive rectal cancer. Computed tomography (CT) showed a circumferential thickening of the lower rectal wall caused by a tumor invading the posterior and side pelvic wall. As we considered R0 resection too difficult, we gave the patient bevacizumab plus FOLFOX4 (oxaliplatin, leucovorin, and 5-fluorouracil). After eight courses, CT showed improvement in the rectal wall thickening but linear thickening of the mesorectal fascia remained. We therefore gave the patient chemoradiotherapy (CRT), and then 10 weeks later performed Hartmann's operation laparoscopically. Microscopic examination revealed that the tumor had been almost replaced by fibrous tissue, with only a few cancer cells left in the subserosa. The circumferential resection margin was free of cancer cells. The patient is doing well after 27 months of follow-up. This case suggests that systemic chemotherapy with FOLFOX4 plus bevacizumab prior to conventional preoperative CRT is a promising strategy for patients with initially unresectable locally advanced rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075663     DOI: 10.1007/s00595-011-0004-9

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  19 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

Review 2.  What is the role for the circumferential margin in the modern treatment of rectal cancer?

Authors:  Iris D Nagtegaal; Phil Quirke
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

3.  Recurrence and survival after total mesorectal excision for rectal cancer.

Authors:  R J Heald; R D Ryall
Journal:  Lancet       Date:  1986-06-28       Impact factor: 79.321

4.  Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.

Authors:  N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

5.  No downstaging after short-term preoperative radiotherapy in rectal cancer patients.

Authors:  C A Marijnen; I D Nagtegaal; E Klein Kranenbarg; J Hermans; C J van de Velde; J W Leer; J H van Krieken
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

6.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 7.  Recent concepts of antiangiogenic therapy.

Authors:  Hiroyuki Konno; Masayoshi Yamamoto; Manabu Ohta
Journal:  Surg Today       Date:  2010-05-23       Impact factor: 2.549

8.  Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

Authors:  Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Journal:  Lancet Oncol       Date:  2010-01-25       Impact factor: 41.316

9.  Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.

Authors:  Hanna K Sanoff; Daniel J Sargent; Megan E Campbell; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

10.  Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.

Authors:  Christos Emmanouilides; Georgia Sfakiotaki; Nikolaos Androulakis; Kostas Kalbakis; Charalambos Christophylakis; Antonia Kalykaki; Lambros Vamvakas; Athanasios Kotsakis; Sofia Agelaki; Eleni Diamandidou; Nikolaos Touroutoglou; Adam Chatzidakis; Vassilis Georgoulias; Dimitris Mavroudis; John Souglakos
Journal:  BMC Cancer       Date:  2007-05-30       Impact factor: 4.430

View more
  1 in total

1.  Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer.

Authors:  Yuichiro Yoshioka; Keisuke Uehara; Tomoki Ebata; Yukihiro Yokoyama; Ayako Mitsuma; Yuichi Ando; Masato Nagino
Journal:  Surg Today       Date:  2013-08-14       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.